Project Grant R01CA299951
Award Date 8/6/26
Completion Date 7/31/31
Dollars Obligated $654K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...
- The National Cancer Institute awarded The University of Kentucky Research Foundation $281,820 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to plan a future intervention trial improving clinical trial education and enrollment for cancer patients. The planning grant supports development of an intervention designed to address persistently low cancer trial enrollment rates in the United States. The award funds preparatory work for a future randomized...
- The National Cancer Institute awarded The Washington University $155,500 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the direct and indirect costs of fertility preservation options for adolescent and young adult cancer survivors, including out-of-pocket fees, transportation, and time off work for parents and caregivers. The research addresses financial hardship among adolescent and young adult cancer survivors, examining how cost...
- The National Cancer Institute awarded the University of Louisville $211,847 on July 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support clinical trial research on perioperative management of cerebral edema in glioblastoma and brain metastases patients. The funded research compares three perioperative edema control strategies in newly diagnosed glioblastoma patients using a randomized trial with AI-powered MRI analysis: dexamethasone (standard of care), no dexamethasone,...
- The National Cancer Institute awarded the University of Louisville $403,686 under Project Grant R21CA299731 on May 1, 2026, to support development of a novel combination therapy for recurrent ovarian cancer. The research, funded through the Cancer Treatment Research program (CFDA 93.395), addresses platinum-resistant ovarian cancer, which recurs in approximately 70 percent of patients within 18 to 24 months following standard cytoreductive surgery and chemotherapy with carboplatin and...
- The National Cancer Institute awarded The University of Kentucky Research Foundation $395,973 on June 9, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing designation R21CA307890) to conduct single-cell-resolution imaging research on drug resistance mechanisms in non-small cell lung cancer patient tumor microenvironments, with emphasis on the interaction between toxic metal pre-exposure and therapeutic resistance in Appalachian populations. The...
- The National Cancer Institute awarded Louisiana State University Health Sciences Center New Orleans $380,554 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a pilot adaptive trial optimizing patient navigation interventions to promote fecal immunochemical test (FIT) colorectal cancer screening among rural residents. The study employs a two-stage sequential multiple assignment randomized trial (SMART) design. Stage 1 evaluates chatbot-based...
- The National Cancer Institute awarded the University of Virginia $514,563 under the Cancer Treatment Research program (CFDA 93.395) on September 1, 2026, to develop adaptive randomization designs for identifying optimal dose combinations in early-phase clinical trials applicable to both oncology and non-oncology agents. The project targets the practical implementation of FDA Project Optimus principles by creating flexible early-stage trial designs that balance treating study participants with...
- The National Cancer Institute awarded Children's Hospital Los Angeles $8.473 million on September 10, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a patient navigation intervention designed to improve transition success among multiply disadvantaged young adult survivors of childhood cancer. The intervention addresses a documented gap in survivorship care: while childhood cancer survival rates exceed 85 percent, treatment-related late effects...
- The National Cancer Institute awarded the University of Kentucky Research Foundation $610,625 on August 5, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to implement a pragmatic effectiveness trial of screening, brief intervention, and referral to treatment (SBIRT) for hazardous alcohol use among cancer survivors. The award funds a five-year study randomizing 1,200 head, neck, and esophageal cancer survivors to either a multilevel intervention called...